
    
      Upon determination of eligibility, all patients will be randomly assigned to one of two
      treatment arms:

      Arm A: Cisplatin, Paclitaxel and Gemcitabine

        -  Cisplatin 75 mg/m2 IV infusion, Day 1

        -  Paclitaxel 175 mg/m2 IV infusion, Day 1

        -  Gemcitabine 1000 mg/m2 IV infusion, Day 1 and 8

      Arm B: Cisplatin, Paclitaxel, Gemcitabine and Avastin (Bevacizumab)

        -  Cisplatin 75 mg/m2 IV infusion, Day 1

        -  Paclitaxel 175 mg/m2 IV infusion, Day 1

        -  Gemcitabine 1000 mg/m2 IV infusion, Day 1 and 8

        -  Bevacizumab 7,5 mg/m2 IV infusion, Day 1

      Patients will be stratified by number of metastatic sites (one versus two or more) and the
      level of Lactate Dehydrogenase (normal versus high).

      The regimens will be repeated every 21 days.
    
  